BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489

Trial Details

NCT ID
NCT06773910
Phase
PHASE2
Sponsor
SCRI Development Innovations, LLC
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BMS-986489
  • Durvalumab
Locations (sample)
  • Daphne, Alabama, United States|30.60353,-87.9036
  • Santa Barbara, California, United States|34.42083,-119.69819
  • Fort Myers, Florida, United States|26.62168,-81.84059
  • Miami, Florida, United States|25.77427,-80.19366
  • Ocala, Florida, United States|29.1872,-82.14009

Key Eligibility Criteria

  • At least 18 years-of-age at the time of signature of the Informed Consent Form (ICF)
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (Appendix A)
  • Histologically or cytologically confirmed pulmonary SCLC, evaluable by RECIST v1.1
  • Limited-stage (LS) disease as determined by positron emission tomography (PET) scan prior to initiation of chemotherapy and radiation therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →